Paul S. Charifson

5.7k citations

55 papers · 4.0k indexed · 1 hit paper · h-index 29

Molecular Biology top 2%
Computational Theory and Mathematics top 0.2%
Organic Chemistry top 2%
Materials Chemistry top 10%
Oncology top 10%

Co-authors: W. Patrick Walters Emanuele Perola Mark A. Murcko David A. Pearlman Lee G. Pedersen Yunyi Wei Christian H. Gross Jonathan D. Parsons
Topics: Protein Structure and Dynamics (11 papers)Cancer therapeutics and mechanisms (11 papers)Computational Drug Discovery Methods (11 papers)
Cited by: Computational Theory and Mathematics Molecular Biology Toxicology
Journals: Proceedings of the National Academy of Sciences Journal of Biological Chemistry Biochemistry
Partner nations: United States France Germany

In The Last Decade

Paul S. Charifson

53 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins

1999 517 citations Paul S. Charifson, Mark A. Murcko et al. Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by Paul S. Charifson

Since Specialization

Citations

This map shows the geographic impact of Paul S. Charifson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul S. Charifson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul S. Charifson more than expected).

Fields of papers citing papers by Paul S. Charifson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul S. Charifson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul S. Charifson. The network helps show where Paul S. Charifson may publish in the future.

Co-authorship network of co-authors of Paul S. Charifson

This figure shows the co-authorship network connecting the top 25 collaborators of Paul S. Charifson. A scholar is included among the top collaborators of Paul S. Charifson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul S. Charifson. Paul S. Charifson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Inhibition of dimeric SARS-CoV-2 Mpro displays positive cooperativity and a mixture of covalent and non-covalent binding 2025 ·iScience ·Krishna Mohan Das,Jun Chen,Paul S. Charifson,Jeremy Green,(unknown),Sanjay C. Panchal,Fan Pu,Alla Korepanova,Abhinav Dubey,(unknown),(unknown),B. Nocek,L. Bigelow,Sarah H. Stubbs,Robert A. Davey,David A. DeGoey,Haribabu Arthanari,Mark Namchuk	0
2	Preclinical characterization of the selective DNA-dependent protein kinase (DNA-PK) inhibitor VX-984 in combination with chemotherapy 2016 ·Annals of Oncology ·(unknown),Shawn Hillier,David Newsome,(unknown),Daigo Takemoto,Yong Gu,William Markland,Russell R. Hoover,(unknown),John P. Maxwell,Scott Z. Fields,Paul S. Charifson,Marina S. Penney,Kirk Tanner	4
3	Preclinical Activity of VX-787, a First-in-Class, Orally Bioavailable Inhibitor of the Influenza Virus Polymerase PB2 Subunit 2014 ·Antimicrobial Agents and Chemotherapy ·Randal A. Byrn,Steven J.M. Jones,(unknown),(unknown),Michael P. Clark,Marc Jacobs,Ann D. Kwong,Mark W. Ledeboer,Joshua R. Leeman,(unknown),Mark A. Murcko,Azin Nezami,Emanuele Perola,René Rijnbrand,Kumkum Saxena,Alice Tsai,Yi Zhou,Paul S. Charifson	149
4	Successful application of serum shift prediction models to the design of dual targeting inhibitors of bacterial gyrase B and topoisomerase IV with improved in vivo efficacy 2014 ·Bioorganic & Medicinal Chemistry Letters ·Emanuele Perola,Dean Stamos,Anne‐Laure Grillot,(unknown),Tiansheng Wang,Arnaud LeTiran,Qing Tang,David D. Deininger,Yusheng Liao,Shi‐Kai Tian,Joseph E. Drumm,David P. Nicolau,Pamela R. Tessier,Nagraj Mani,Trudy H. Grossman,Paul S. Charifson	8
5	Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: Aminoalkoxypyrimidine carboxamides 2012 ·Bioorganic & Medicinal Chemistry Letters ·Wenxin Gu,Tiansheng Wang,François Maltais,Brian Ledford,Joseph M. Kennedy,Yunyi Wei,Christian H. Gross,Jonathan D. Parsons,(unknown),S J Ryan Arends,Cameron Stuver Moody,Emanuele Perola,Jeremy Green,Paul S. Charifson	12
6	Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part 2: 4-Amino-pyrido[2,3-d]pyrimidin-5(8H)-ones 2012 ·Bioorganic & Medicinal Chemistry Letters ·Tiansheng Wang,(unknown),Wenxin Gu,Hardwin O’Dowd,Yunyi Wei,Emanuele Perola,Jonathan D. Parsons,Christian H. Gross,Cameron Stuver Moody,S J Ryan Arends,Paul S. Charifson	13
7	Discovery of pyrazolthiazoles as novel and potent inhibitors of bacterial gyrase 2010 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Michael C. Badia,S.F. Bellon,Anne‐Laure Grillot,Christian H. Gross,Trudy H. Grossman,Nagraj Mani,Jonathan D. Parsons,Dean Stamos,Martin Trudeau,Yunyi Wei,Paul S. Charifson	85
8	FURSMASA: A new approach to rapid scoring functions that uses a MD‐averaged potential energy grid and a solvent‐accessible surface area term with parameters GA fit to experimental data 2008 ·Proteins Structure Function and Bioinformatics ·David A. Pearlman,B. Govinda Rao,Paul S. Charifson	7
9	(S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2 R,3 S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhibitor, Exhibits Potent Anti-Inflammatory Activities by Inhibiting the Release of IL-1β and IL-18 2007 ·Journal of Pharmacology and Experimental Therapeutics ·(unknown),(unknown),Mark Namchuk,John R. Pollard,Pamella J. Ford,George Ku,Caroline J. Decker,Paul S. Charifson,Peter Weber,Ursula A. Germann,Keisuke Kuida,John C.R. Randle	250
10	Filtering databases and chemical libraries 2002 ·Journal of Computer-Aided Molecular Design ·Paul S. Charifson,W. Patrick Walters	44
11	Filtering databases and chemical libraries 2000 ·Molecular Diversity ·Paul S. Charifson,W. Patrick Walters	12
12	The structures of caspases-1, -3, -7 and -8 reveal the basis for substrate and inhibitor selectivity 2000 ·Chemistry & Biology ·Yunyi Wei,Ted Fox,(unknown),(unknown),Joyce T. Coll,Julian M.C. Golec,Lora Swenson,Keith P. Wilson,Paul S. Charifson	166
13	The formation of a covalent complex between a dipeptide ligand and the src SH2 domain 1998 ·Bioorganic & Medicinal Chemistry Letters ·Krystal J. Alligood,Paul S. Charifson,Renae M. Crosby,Thomas G. Consler,Paul L. Feldman,Robert T. Gampe,Tona M. Gilmer,Steven R. Jordan,(unknown),Christopher Mohr,Michael Peel,Warren J. Rocque,(unknown),David W. Rusnak,Lisa M. Shewchuk,Daniel D. Sternbach	13
14	Practical Application of Computer-Aided Drug Design 1997 ·Paul S. Charifson	136
15	Role of Glutamine-61 in the Hydrolysis of GTP by p21H-ras: An Experimental and Theoretical Study 1994 ·Biochemistry ·Matthias Frech,Tom Darden,Lee G. Pedersen,C. K. Foley,Paul S. Charifson,M W Anderson,A. Wittinghofer	112
16	3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats 1994 ·Journal of Medicinal Chemistry ·Timothy M. Willson,Brad R. Henke,(unknown),Paul S. Charifson,Kenneth W. Batchelor,Dennis B. Lubahn,Linda B. Moore,(unknown),Howard R. Sauls,(unknown),Steven G. Wolfe,Philip G. Baer	115
17	Conformational Analysis, Pharmacophore Identification, and Comparative Molecular Field Analysis of Ligands for the Neuromodulatory .sigma.3 Receptor 1994 ·Journal of Medicinal Chemistry ·(unknown),Paul S. Charifson,(unknown),Nora S. Kula,Andrew T. McPhail,R J Baldessarini,Raymond G. Booth,Steven D. Wyrick	42
18	Simulation of the solution structure of the H-ras p21-GTP complex 1992 ·Biochemistry ·C. K. Foley,Lee G. Pedersen,Paul S. Charifson,Tom Darden,A. Wittinghofer,E.F. Pai,M W Anderson	38
19	Conformational analysis and molecular modeling of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as D1 dopamine receptor ligands 1989 ·Journal of Medicinal Chemistry ·Paul S. Charifson,J. Phillip Bowen,Steven D. Wyrick,Andrew J. Hoffman,(unknown),Andrew T. McPhail,Richard B. Mailman	41
20	Synthesis and pharmacological characterization of 1-phenyl-, 4-phenyl-, and 1-benzyl-1,2,3,4-tetrahydroisoquinolines as dopamine receptor ligands 1988 ·Journal of Medicinal Chemistry ·Paul S. Charifson,Steven D. Wyrick,Andrew J. Hoffman,Rosa Maria A. Simmons,J. Phillip Bowen,Darryl McDougald,Richard B. Mailman	32

About Paul S. Charifson

Paul S. Charifson is a scholar working on Molecular Medicine, Toxicology and Computational Theory and Mathematics, having authored 55 papers that have together received 4.0k indexed citations. Recurring topics across this work include Protein Structure and Dynamics (11 papers), Cancer therapeutics and mechanisms (11 papers) and Computational Drug Discovery Methods (11 papers). The work is most often cited by research in Computational Theory and Mathematics (1.3k citations), Molecular Biology (2.9k citations) and Toxicology (134 citations). Paul S. Charifson has collaborated with scholars based in United States, France and Germany. Frequent co-authors include W. Patrick Walters, Emanuele Perola, Mark A. Murcko, David A. Pearlman, Lee G. Pedersen, Yunyi Wei, Christian H. Gross, Jonathan D. Parsons, Lora Swenson and Steven D. Wyrick. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact